Sensory-Predominant Chronic Inflammatory Demyelinating Polyradiculoneuropathy

Sensory-predominant chronic inflammatory demyelinating polyradiculoneuropathy is an autoimmune disorder in which the body’s immune system attacks the myelin sheath of peripheral sensory nerves more than motor fibers. This causes progressive numbness, tingling, and balance problems without significant muscle weakness, evolving over at least eight weeks and fulfilling CIDP criteria with primarily sensory involvement medicalaffairs.cslbehring.com.

Sensory-predominant CIDP is a variant of chronic inflammatory demyelinating polyradiculoneuropathy in which sensory nerves are affected more severely than motor nerves. In this condition, the immune system mistakenly attacks the myelin sheath—a fatty insulating layer around peripheral nerves—leading to slowed or blocked nerve conduction. Patients typically experience numbness, tingling, and burning pain, often starting in the feet and hands and progressing proximally. Over time, demyelination can cause sensory ataxia (loss of balance due to impaired sensation), resulting in unsteady gait and falls.

---

Types

Pure Sensory CIDP
In pure sensory CIDP, sensory nerve conduction abnormalities occur in at least two nerves, while motor conduction in at least four nerves remains entirely normal. Patients exhibit profound sensory loss—vibration, position, and touch—without any detectable motor nerve involvement medicalaffairs.cslbehring.com.

Sensory-Predominant CIDP
Sensory-predominant CIDP is diagnosed when sensory conduction criteria are met in two or more nerves and motor conduction criteria are fulfilled in one or two nerves. One nerve fulfilling motor criteria indicates possible sensory-predominant CIDP; two nerves confirm diagnostic certainty medicalaffairs.cslbehring.com.

---

Causes

1. Idiopathic Autoimmunity
   Most cases arise without a known trigger. In these patients, immune cells mistakenly target peripheral nerve myelin proteins, leading to chronic demyelination and sensory dysfunction en.wikipedia.org.

2. Genetic Predisposition (HLA Variants)
   Certain human leukocyte antigen (HLA) types increase susceptibility to autoimmune nerve attack. Genetic studies suggest HLA-DR and HLA-DQ alleles are overrepresented in CIDP en.wikipedia.org.

3. Campylobacter jejuni Infection
   This common bacterial gastrointestinal infection can precipitate an aberrant immune response that cross-reacts with nerve myelin, triggering sensory-predominant demyelination en.wikipedia.org.

4. Cytomegalovirus (CMV)
   CMV infection may induce molecular mimicry, where CMV antigens resemble myelin proteins, provoking immune-mediated nerve damage en.wikipedia.org.

5. Epstein–Barr Virus (EBV)
   EBV can trigger widespread immune activation; in susceptible individuals, this may include antibodies or T cells targeting myelin components en.wikipedia.org.

6. HIV Infection
   HIV causes immune dysregulation that sometimes leads to demyelinating neuropathies, including sensory-predominant CIDP, through chronic inflammation en.wikipedia.org.

7. Hepatitis C Virus
   Chronic hepatitis C is associated with mixed cryoglobulinemia and immune complex deposition, which can involve peripheral nerve myelin en.wikipedia.org.

8. Hepatitis B Virus
   Although less common, hepatitis B can trigger autoimmune neuropathies via immune complex formation and complement activation en.wikipedia.org.

9. Influenza and Other Viral Illnesses
   Viral infections like influenza may precipitate aberrant immune responses against nerve myelin through molecular mimicry en.wikipedia.org.

10. COVID-19 Infection
    Emerging reports link SARS-CoV-2 infection with demyelinating neuropathies, possibly due to post-infectious immune activation en.wikipedia.org.

11. Lyme Disease (Borrelia burgdorferi)
    Borrelia infection can lead to neuropathy; immune responses to spirochetal antigens may cross-react with nerve myelin en.wikipedia.org.

12. Vaccinations
    Rarely, vaccines (e.g., tetanus, influenza) can trigger autoimmunity via mimicry, leading to sensory demyelination in predisposed patients en.wikipedia.org.

13. Monoclonal Gammopathy of Undetermined Significance (MGUS)
    MGUS can produce antibodies that bind myelin proteins, causing chronic demyelination en.wikipedia.org.

14. Lymphoma and Leukemia
    Hematologic cancers may provoke paraneoplastic immune reactions, targeting peripheral nerve sheaths en.wikipedia.org.

15. Multiple Myeloma
    Malignant plasma cells secrete monoclonal proteins that can bind myelin, leading to sensory neuropathy en.wikipedia.org.

16. Waldenström’s Macroglobulinemia
    High-titer IgM can deposit on nerves or activate complement, injuring sensory fibers en.wikipedia.org.

17. Sjögren’s Syndrome
    Exocrine gland–targeted autoimmunity often extends to peripheral nerves, causing demyelination and sensory loss en.wikipedia.org.

18. Systemic Lupus Erythematosus (SLE)
    SLE-associated antibodies and immune complexes can attack myelin, leading to sensory neuropathy en.wikipedia.org.

19. Diabetes Mellitus
    Chronic hyperglycemia induces inflammation and may predispose to immune-mediated demyelination in some individuals en.wikipedia.org.

20. Sarcoidosis
    Noncaseating granulomas in peripheral nerves can disrupt myelin and provoke autoimmune demyelination en.wikipedia.org.

---

Symptoms

1. Numbness in Extremities
   A common early symptom is a persistent loss of feeling in hands and feet, which may spread proximally over time en.wikipedia.org.

2. Tingling (Paresthesia)
   Patients often feel pins and needles or “falling asleep” sensations in affected limbs en.wikipedia.org.

3. Burning Pain
   Some experience burning or scalding sensations, reflecting small-fiber involvement en.wikipedia.org.

4. Dysesthesia
   Unpleasant abnormal sensations, such as electric shocks, occur spontaneously or with light touch en.wikipedia.org.

5. Hyperesthesia
   Heightened sensitivity to stimuli, where normal touch feels exaggerated or painful en.wikipedia.org.

6. Loss of Vibration Sense
   Patients cannot feel a vibrating tuning fork over bony prominences en.wikipedia.org.

7. Loss of Proprioception
   Impaired joint position sense leads to difficulty knowing limb placement without visual cues en.wikipedia.org.

8. Sensory Ataxia
   Coordination problems arise when walking without visual feedback, worsening in the dark en.wikipedia.org.

9. Gait Unsteadiness
   An unsteady or staggering walk occurs due to impaired sensory input from the feet en.wikipedia.org.

10. Balance Problems
    Difficulty standing still, especially with eyes closed, reflecting impaired position sense en.wikipedia.org.

11. Allodynia
    Pain from normally nonpainful stimuli, such as light touch or clothing en.wikipedia.org.

12. Neuropathic Pain
    Aching or shooting pain often follows a glove-and-stocking distribution en.wikipedia.org.

13. Impaired Temperature Sensation
    Reduced ability to distinguish hot from cold, increasing injury risk en.wikipedia.org.

14. Reduced Pinprick Sensation
    Diminished pain perception when tested with a pin or pinwheel en.wikipedia.org.

15. Hyporeflexia
    Deep tendon reflexes are diminished or absent, reflecting nerve dysfunction en.wikipedia.org.

16. Deep Aching in Limbs
    A constant deep ache often worsens at rest or nighttime en.wikipedia.org.

17. Electric Shock-Like Sensations
    Sudden lancinating pains may shoot along the limbs en.wikipedia.org.

18. Sensory Fatigue
    Patients describe a tiring or heavy sensation in limbs after minimal activity en.wikipedia.org.

19. Difficulty with Fine Touch
    Challenges detecting light touch or localization of touch on skin en.wikipedia.org.

20. Tremor or Pseudotremor
    Postural or intention tremor may occur due to impaired proprioceptive feedback en.wikipedia.org.

---

Diagnostic Tests

Physical Exam

1. Deep Tendon Reflex Testing
   Using a reflex hammer, the examiner assesses reflex strength; reduced or absent reflexes suggest demyelination en.wikipedia.org.

2. Romberg Test
   Patients stand with feet together and eyes closed; loss of balance indicates impaired proprioception en.wikipedia.org.

3. Gait Assessment
   Observation of walking reveals sensory ataxia—wide-based, unsteady gait especially when vision is blocked en.wikipedia.org.

4. Sensory Examination
   Systematic testing of light touch, pinprick, vibration, and temperature along limbs to map sensory deficits en.wikipedia.org.

5. Pinprick Sensation Assessment
   A pin or sharp instrument lightly pricked on skin gauges pain perception; diminished in affected areas en.wikipedia.org.

6. Light Touch Examination
   A wisp of cotton tests the ability to perceive gentle pressure en.wikipedia.org.

7. Proprioception Testing
   Examiner moves a patient’s finger or toe up and down with eyes closed to assess position sense en.wikipedia.org.

8. Vibration Sense Testing
   A 128-Hz tuning fork placed on bony prominences assesses vibration detection; reduced in sensory CIDP en.wikipedia.org.

Manual Tests

9. Manual Muscle Testing (MRC Scale)
   Grading muscle strength from 0 to 5; typically normal or mildly reduced in sensory-predominant CIDP en.wikipedia.org.

10. Upper Limb Strength Testing
    Manual resistance applied to shoulder, elbow, and wrist movements to rule out motor involvement en.wikipedia.org.

11. Lower Limb Strength Testing
    Resistance against hip, knee, and ankle movements evaluates subtle motor weakness en.wikipedia.org.

12. Semmes-Weinstein Monofilament Test
    Standardized nylon filaments applied to the skin quantify light-touch threshold en.wikipedia.org.

13. Two-Point Discrimination Test
    Measures the minimal distance at which two simultaneous touches are felt as separate en.wikipedia.org.

14. Tuning Fork Discrimination Test
    Compares vibration sense on different sites to detect gradient of sensory loss en.wikipedia.org.

15. Temperature Discrimination Test
    Cold and warm metal objects applied alternately to skin assess temperature perception en.wikipedia.org.

16. Joint Position Sense Test
    Evaluates large-fiber function by moving digits and asking for position feedback en.wikipedia.org.

Lab & Pathological Tests

17. Cerebrospinal Fluid (CSF) Protein Level
    Elevated CSF protein (>45 mg/dL) without significant pleocytosis supports CIDP diagnosis cureus.com.

18. CSF Cell Count
    Typically normal (<10 cells/µL); helps exclude infectious causes cureus.com.

19. Serum Protein Electrophoresis
    Identifies monoclonal gammopathies that can underlie CIDP variants en.wikipedia.org.

20. Immunofixation Electrophoresis
    Detects low-level monoclonal proteins missed on standard electrophoresis en.wikipedia.org.

21. Anti-Ganglioside Antibody Panel
    Tests for anti-GM1, anti-GD1a, and anti-GQ1b antibodies; may be positive in CIDP variants en.wikipedia.org.

22. Erythrocyte Sedimentation Rate (ESR)
    Often normal; elevated values suggest alternate inflammatory neuropathies en.wikipedia.org.

23. C-Reactive Protein (CRP)
    Generally normal in CIDP; elevated in systemic inflammation en.wikipedia.org.

24. Antinuclear Antibody (ANA)
    Screens for connective tissue diseases associated with neuropathy en.wikipedia.org.

25. HIV, HBV, HCV Serologies
    Exclude viral triggers of neuropathy en.wikipedia.org.

26. Lyme Serology
    Tests for Borrelia antibodies when Lyme disease is suspected en.wikipedia.org.

27. Vitamin B12 Level
    Rules out B12 deficiency neuropathy en.wikipedia.org.

28. Thyroid Function Tests
    Hypothyroidism can cause neuropathy; checking TSH helps exclude it en.wikipedia.org.

Electrodiagnostic Tests

29. Nerve Conduction Velocity (NCV)
    Measures speed of impulse; slowed velocity indicates demyelination en.wikipedia.org.

30. Distal Motor Latency
    Prolonged latency to distal muscle response suggests focal demyelination en.wikipedia.org.

31. F-Wave Latency
    Prolonged or absent F waves reflect proximal nerve root demyelination en.wikipedia.org.

32. Conduction Block Detection
    Reduction in CMAP amplitude between proximal and distal stimulation sites denotes segmental demyelination en.wikipedia.org.

33. Temporal Dispersion Measurement
    Broadening of CMAP waveform indicates asynchronous conduction from demyelinated fibers en.wikipedia.org.

34. Compound Muscle Action Potential (CMAP) Amplitude
    Decreased amplitude may reflect axonal loss secondary to chronic demyelination en.wikipedia.org.

35. Sensory Nerve Action Potential (SNAP) Measurement
    Reduced or absent SNAPs in sensory nerves confirm sensory fiber involvement en.wikipedia.org.

36. Electromyography (EMG)
    Detects fibrillation potentials or positive sharp waves when chronic denervation is present en.wikipedia.org.

Imaging Tests

37. MRI of Spinal Nerve Roots
    T2-weighted MRI shows root hypertrophy or enhancement in cervical and lumbosacral regions uems-neuroboard.org.

38. MR Neurography
    High-resolution imaging of peripheral nerves reveals focal enlargements consistent with demyelination sciencedirect.com.

39. Ultrasound of Peripheral Nerves
    High-frequency ultrasound shows nerve enlargement and loss of fascicular pattern en.wikipedia.org.

40. CT Myelography
    May visualize nerve root enlargement when MRI is contraindicated en.wikipedia.org.

Non-Pharmacological Treatments

Non-drug strategies form an essential part of managing sensory-predominant CIDP. They support nerve healing, maintain function, reduce pain, and improve quality of life.

A. Physiotherapy & Electrotherapy Therapies

1. Neuromuscular Re-education

   • Description: Guided exercises focusing on retraining nerve–muscle pathways.

   • Purpose: Restore coordinated movement and proprioception.

   • Mechanism: Repeated, task-oriented practice enhances neuroplasticity, reinforcing functional motor patterns.

2. Balance Training with Foam Pads

   • Description: Standing and walking on unstable surfaces like foam or wobble boards.

   • Purpose: Improve sensory feedback and stability.

   • Mechanism: Challenging proprioceptors forces the central nervous system to adapt, enhancing postural control.

3. TENS (Transcutaneous Electrical Nerve Stimulation)

   • Description: Low-voltage electrical currents applied via surface electrodes.

   • Purpose: Alleviate neuropathic pain and reduce sensory disturbances.

   • Mechanism: Activates large-diameter afferent fibers to inhibit pain transmission (“gate control” theory) and stimulates endorphin release.

4. Neuromuscular Electrical Stimulation (NMES)

   • Description: Electrical pulses elicit muscle contractions.

   • Purpose: Prevent muscle atrophy secondary to disuse.

   • Mechanism: Induces repetitive contraction—relaxation cycles—maintaining muscle mass and neuromuscular junction integrity.

5. Pulsed Ultrasound Therapy

   • Description: High-frequency sound waves delivered intermittently.

   • Purpose: Promote local circulation and nerve healing.

   • Mechanism: Mechanical vibrations increase blood flow, reduce edema, and stimulate collagen synthesis in perineural tissues.

6. Contrast Bath Therapy

   • Description: Alternating immersion of limbs in warm and cool water.

   • Purpose: Reduce pain and swelling in hands and feet.

   • Mechanism: Vasodilation (warm) followed by vasoconstriction (cool) improves fluid dynamics and modulates nociceptor activity.

7. Scar Tissue Mobilization

   • Description: Manual techniques to mobilize perineural adhesions.

   • Purpose: Prevent tethering of nerves and maintain gliding.

   • Mechanism: Gentle stretching and soft-tissue manipulation break down fibrotic bands around nerves.

8. Low-Level Laser Therapy (LLLT)

   • Description: Low-intensity light directed at affected nerves.

   • Purpose: Reduce inflammation and accelerate repair.

   • Mechanism: Photobiomodulation alters mitochondrial activity, enhancing ATP production and reducing pro-inflammatory cytokines.

9. Diathermy (Shortwave or Microwave)

   • Description: Deep heating via electromagnetic fields.

   • Purpose: Increase tissue extensibility and relieve stiffness.

   • Mechanism: Heat penetrates deep tissues, improving blood flow and reducing neural edema.

10. Soft Tissue Massage

    • Description: Manual kneading and stroking of muscles and connective tissue.

    • Purpose: Decrease muscle tension and improve local circulation.

    • Mechanism: Mechanical pressure stimulates mechanoreceptors, reducing sympathetic tone and promoting relaxation.

11. Joint Mobilization

    • Description: Controlled, passive oscillatory movements of joints.

    • Purpose: Maintain joint range of motion and reduce stiffness.

    • Mechanism: Gentle traction and gliding stretch joint capsules, enhancing synovial fluid circulation.

12. Cryotherapy

    • Description: Application of cold packs to affected areas.

    • Purpose: Alleviate acute pain flare-ups.

    • Mechanism: Cold reduces nerve conduction velocity and releases endorphins, dampening nociceptive signals.

13. Hydrotherapy

    • Description: Exercises performed in a warm pool.

    • Purpose: Support limb weight, allow gentle movement, reduce pain on movement.

    • Mechanism: Buoyancy decreases gravity’s load on joints and muscles, facilitating range-of-motion exercises.

14. Vibration Therapy

    • Description: Application of mechanical vibrations to muscles.

    • Purpose: Stimulate proprioceptive feedback and circulation.

    • Mechanism: Vibratory stimuli activate muscle spindles, improving postural control and blood flow.

15. Functional Electrical Stimulation (FES)

    • Description: Triggered electrical pulses during functional tasks (e.g., walking).

    • Purpose: Reinforce correct gait patterns and prevent foot drop.

    • Mechanism: Synchronized stimulation of dorsiflexors improves timing of muscle activation during gait.

B. Exercise Therapies

16. Aerobic Walking Programs

    • Description: Structured walking sessions on treadmill or ground.

    • Purpose: Enhance cardiovascular fitness and nerve perfusion.

    • Mechanism: Increases oxygen delivery to peripheral nerves, supporting repair.

17. Resistance Band Strengthening

    • Description: Progressive resistance exercises using elastic bands.

    • Purpose: Maintain muscle strength around affected joints.

    • Mechanism: Isotonic contractions improve muscle fiber recruitment and joint stability.

18. Aquatic Resistance Training

    • Description: Water-based exercises using paddles or water weights.

    • Purpose: Build strength with reduced joint stress.

    • Mechanism: Water viscosity provides uniform resistance and proprioceptive input.

19. Tai Chi

    • Description: Slow, flowing martial-art–based movements.

    • Purpose: Improve balance, proprioception, and mind-body awareness.

    • Mechanism: Shifting weight and coordinating breath with movement enhances sensorimotor integration.

20. Sit-to-Stand Repetitions

    • Description: Repeated rising from a chair to standing.

    • Purpose: Strengthen quadriceps and hip extensors.

    • Mechanism: Functional loading improves lower-limb power and coordination.

21. Heel-to-Toe Tandem Walking

    • Description: Walking in a straight line placing heel of one foot to toe of the other.

    • Purpose: Challenge dynamic balance and gait control.

    • Mechanism: Narrows base of support, forcing reliance on sensory feedback.

22. Core Stabilization Exercises

    • Description: Planks, pelvic tilts, and abdominal bracing.

    • Purpose: Stabilize trunk to support limb movements.

    • Mechanism: Strengthens deep stabilizers, improving postural control and reducing compensatory strain.

C. Mind-Body Therapies

23. Guided Imagery

    • Description: Visualization of calming, healing scenarios.

    • Purpose: Reduce stress-related pain amplification.

    • Mechanism: Activates parasympathetic pathways, lowering cortisol and muscle tension.

24. Mindfulness Meditation

    • Description: Present-moment, nonjudgmental awareness exercises.

    • Purpose: Improve pain coping and emotional well-being.

    • Mechanism: Alters neural processing in pain networks, reducing catastrophizing.

25. Progressive Muscle Relaxation

    • Description: Sequential tensing and relaxing of muscle groups.

    • Purpose: Release muscle tightness associated with chronic pain.

    • Mechanism: Enhances interoceptive awareness and reduces sympathetic arousal.

26. Biofeedback

    • Description: Real-time monitoring of physiological functions (e.g., muscle tension) with feedback.

    • Purpose: Enable patients to self-regulate muscle tone and stress.

    • Mechanism: Visual/auditory cues foster voluntary control over autonomic responses.

D. Educational & Self-Management

27. Disease Education Sessions

    • Description: One-on-one or group classes on CIDP pathophysiology and management.

    • Purpose: Empower patients with knowledge about their condition.

    • Mechanism: Understanding disease processes improves adherence to therapies and early recognition of relapses.

28. Energy Conservation Training

    • Description: Techniques for pacing activities and planning rest breaks.

    • Purpose: Prevent fatigue exacerbations.

    • Mechanism: Balances activity/rest cycles, reducing cumulative neural stress.

29. Pain Management Workshops

    • Description: Instruction in pacing, relaxation, and goal setting.

    • Purpose: Provide behavioral tools to handle chronic pain.

    • Mechanism: Cognitive-behavioral strategies modify pain perception and coping.

30. Home Exercise Program Planning

    • Description: Customized exercise schedule with written instructions.

    • Purpose: Maintain consistency between clinic visits.

    • Mechanism: Structured routines reinforce neural and muscular adaptations.

---

Evidence-Based Drugs

Below are the primary pharmacotherapies used in sensory-predominant CIDP, with typical adult dosages, drug classes, timing, and key side effects.

1. Prednisone (Corticosteroid)

   • Dosage: 1 mg/kg/day orally (max 80 mg) initially, then taper

   • Timing: Morning with food

   • Side Effects: Weight gain, osteoporosis, hyperglycemia, hypertension

2. Methylprednisolone (Corticosteroid)

   • Dosage: 1 g IV daily for 3–5 days, then oral taper

   • Timing: Inpatient infusion

   • Side Effects: Fluid retention, mood changes, immunosuppression

3. Intravenous Immunoglobulin (IVIg)

   • Dosage: 2 g/kg total over 2–5 days, then maintenance 1 g/kg every 2–4 weeks

   • Timing: Infusion under monitoring

   • Side Effects: Headache, aseptic meningitis, thromboembolism, renal impairment

4. Plasma Exchange (PLEX)

   • Dosage: 4–6 exchanges of 50 mL/kg over 1–2 weeks

   • Timing: Every other day

   • Side Effects: Hypotension, coagulopathy, infection risk

5. Azathioprine (Immunosuppressant)

   • Dosage: 2–3 mg/kg/day orally

   • Timing: Twice daily with food

   • Side Effects: Bone marrow suppression, hepatotoxicity, GI upset

6. Mycophenolate Mofetil (Immunosuppressant)

   • Dosage: 1 g twice daily orally

   • Timing: Morning and evening

   • Side Effects: Diarrhea, leukopenia, increased infection risk

7. Methotrexate (Antimetabolite)

   • Dosage: 15–25 mg weekly orally or subcutaneously

   • Timing: Once weekly

   • Side Effects: Hepatotoxicity, pulmonary fibrosis, cytopenias

8. Cyclosporine (Calcineurin Inhibitor)

   • Dosage: 3–5 mg/kg/day orally divided

   • Timing: Twice daily

   • Side Effects: Nephrotoxicity, hypertension, tremor

9. Tacrolimus (Calcineurin Inhibitor)

   • Dosage: 0.1–0.2 mg/kg/day orally in two doses

   • Timing: Morning and evening

   • Side Effects: Nephrotoxicity, neurotoxicity, hyperglycemia

10. Cyclophosphamide (Alkylating Agent)

    • Dosage: 1 g/m² IV monthly

    • Timing: Inpatient infusion

    • Side Effects: Hemorrhagic cystitis, infertility, marrow suppression

11. Rituximab (Anti-CD20 Monoclonal Antibody)

    • Dosage: 375 mg/m² IV weekly × 4 doses

    • Timing: Weekly infusions

    • Side Effects: Infusion reactions, infection risk

12. Eculizumab (Complement Inhibitor)

    • Dosage: 900 mg IV weekly × 4, then 1200 mg every 2 weeks

    • Timing: Infusion center

    • Side Effects: Meningococcal infection risk

13. Fingolimod (S1P Receptor Modulator)

    • Dosage: 0.5 mg orally daily

    • Timing: Once daily

    • Side Effects: Bradycardia, macular edema, infection

14. Interferon-β1a (Immunomodulator)

    • Dosage: 30 µg IM weekly

    • Timing: Once weekly

    • Side Effects: Flu-like symptoms, injection-site reactions

15. Alemtuzumab (Anti-CD52 Monoclonal Antibody)

    • Dosage: 12 mg/day IV × 5 days, repeat 12 mg/day × 3 days at 12 months

    • Timing: Inpatient infusions

    • Side Effects: Autoimmune cytopenias, infusion reactions

16. Intravenous Cyclophosphamide Pulse

    • Dosage: 500 mg/m² IV every 4 weeks

    • Timing: Monthly infusions

    • Side Effects: Similar to above, with lower cumulative dose

17. Venetoclax (BCL-2 Inhibitor) – Experimental

    • Dosage: 50–400 mg orally daily

    • Timing: Once daily

    • Side Effects: Neutropenia, tumor lysis syndrome

18. Cladribine (Purinergic Antagonist)

    • Dosage: 0.07 mg/kg/day SC × 5 days, repeat at month 1

    • Timing: Two-course regimen

    • Side Effects: Lymphopenia, infection risk

19. Ofatumumab (Anti-CD20 Monoclonal Antibody)

    • Dosage: 20 mg SC monthly after loading doses

    • Timing: First three doses weekly, then monthly

    • Side Effects: Injection reactions, infections

20. Sirolimus (mTOR Inhibitor)

    • Dosage: 2 mg orally daily, adjust to trough 5–15 ng/mL

    • Timing: Once daily

    • Side Effects: Hyperlipidemia, thrombocytopenia, delayed wound healing

---

Dietary Molecular Supplements

1. Alpha-Lipoic Acid

   • Dosage: 600 mg orally daily

   • Function: Antioxidant to reduce nerve oxidative stress

   • Mechanism: Scavenges free radicals and regenerates other antioxidants, protecting myelin.

2. Vitamin B12 (Methylcobalamin)

   • Dosage: 1000 µg IM monthly or 2000 µg oral daily

   • Function: Supports myelin synthesis

   • Mechanism: Cofactor for methylation of myelin basic protein, promoting repair.

3. Omega-3 Fatty Acids

   • Dosage: 1–2 g EPA/DHA orally daily

   • Function: Anti-inflammatory support

   • Mechanism: Modulates eicosanoid pathways, reducing pro-inflammatory cytokine production.

4. Acetyl-L-Carnitine

   • Dosage: 500 mg orally twice daily

   • Function: Enhances nerve energy metabolism

   • Mechanism: Transports fatty acids into mitochondria, improving ATP production in neurons.

5. Vitamin D3

   • Dosage: 1000–2000 IU orally daily (adjust per levels)

   • Function: Immunomodulatory

   • Mechanism: Regulates T-cell differentiation and reduces pro-inflammatory responses.

6. N-Acetylcysteine

   • Dosage: 600 mg orally twice daily

   • Function: Glutathione precursor for antioxidant defense

   • Mechanism: Increases intracellular glutathione, protecting Schwann cells from oxidative damage.

7. Coenzyme Q10

   • Dosage: 100 mg orally daily

   • Function: Mitochondrial support

   • Mechanism: Facilitates electron transport chain activity, supporting nerve cell energy needs.

8. Curcumin (Turmeric Extract)

   • Dosage: 500 mg standardized extract orally twice daily

   • Function: Anti-inflammatory and neuroprotective

   • Mechanism: Inhibits NF-κB pathway, reducing cytokine release and myelin damage.

9. Magnesium L-Threonate

   • Dosage: 144 mg elemental magnesium orally daily

   • Function: Nerve excitability modulation

   • Mechanism: Regulates calcium channel activity, stabilizing neuronal membranes.

10. Green Tea Polyphenols (EGCG)

    • Dosage: 300 mg EGCG orally daily

    • Function: Antioxidant and anti-inflammatory

    • Mechanism: Inhibits pro-inflammatory enzymes (COX-2, LOX) and scavenges free radicals.

---

Novel & Regenerative Therapies

These agents address complications of long-term immunotherapy (e.g., bone loss), or aim to promote nerve regeneration.

1. Alendronate (Bisphosphonate)

   • Dosage: 70 mg orally once weekly

   • Function: Prevents osteoporosis from chronic steroids

   • Mechanism: Inhibits osteoclast-mediated bone resorption.

2. Zoledronic Acid (Bisphosphonate)

   • Dosage: 5 mg IV annually

   • Function: Long-term bone density preservation

   • Mechanism: Binds hydroxyapatite, reducing osteoclast activity.

3. Risedronate (Bisphosphonate)

   • Dosage: 35 mg orally weekly

   • Function: Maintains bone mass

   • Mechanism: Similar to other bisphosphonates in blocking resorption.

4. Recombinant Human Nerve Growth Factor (rhNGF) (Regenerative)

   • Dosage: Experimental SC injections weekly

   • Function: Stimulates Schwann cell support and axonal regrowth

   • Mechanism: Binds TrkA receptors, promoting neuron survival and myelination.

5. Platelet-Rich Plasma (PRP) Injections (Regenerative)

   • Dosage: 3–5 mL PRP injected monthly

   • Function: Enhances local healing factors

   • Mechanism: Delivers concentrated growth factors (PDGF, TGF-β) to perineural tissue.

6. Hyaluronic Acid Injections (Viscosupplementation)

   • Dosage: 1 mL perineural injection monthly

   • Function: Reduce perineural fibrosis and facilitate gliding

   • Mechanism: Provides lubrication around nerves, preventing tethering.

7. Hylan G-F 20 (Viscosupplementation)

   • Dosage: 2 mL perineural injection every 6 weeks

   • Function: Similar to HA, prolonged effect

   • Mechanism: High molecular weight HA derivative, enhances perineural mobility.

8. Mesenchymal Stem Cell Therapy (Stem Cell Drug)

   • Dosage: 1–5 × 10^6 cells/kg IV infusion quarterly

   • Function: Modulate immune response and support repair

   • Mechanism: MSCs secrete anti-inflammatory cytokines and neurotrophic factors.

9. Hematopoietic Stem Cell Transplantation (HSCT)

   • Dosage: Autologous transplant following conditioning

   • Function: Reset aberrant immune system

   • Mechanism: Eradicates pathogenic lymphocytes, allows reconstitution without autoreactivity.

10. Neural Progenitor Cell Transplants (Experimental)

    • Dosage: 10^5–10^6 cells targeted near nerve roots

    • Function: Replace damaged Schwann cells

    • Mechanism: Differentiate into myelin-forming cells and secrete neurotrophic factors.

---

Surgical Procedures

While CIDP is primarily medical, certain surgical interventions may address complications or diagnostic needs.

1. Nerve Biopsy

   • Procedure: Excision of a small sensory nerve (e.g., sural) under local anesthesia.

   • Benefits: Provides definitive histopathological diagnosis, confirming demyelination and inflammation.

2. Carpal Tunnel Release

   • Procedure: Division of the transverse carpal ligament.

   • Benefits: Relieves median nerve compression, improving hand sensation in patients with coexisting entrapment.

3. Tendon Transfer for Foot Drop

   • Procedure: Transfer of tibialis posterior tendon to dorsum of foot.

   • Benefits: Restores active dorsiflexion in patients with severe peroneal neuropathy.

4. Intrathecal Baclofen Pump Implantation

   • Procedure: Surgical placement of pump and catheter into intrathecal space.

   • Benefits: Manages severe spasticity secondary to long-term steroid use or neuropathy.

5. Spinal Cord Stimulator (SCS) Implant

   • Procedure: Epidural electrode placement connected to subcutaneous pulse generator.

   • Benefits: Reduces chronic neuropathic pain by modulating dorsal column activity.

6. Tarsal Tunnel Release

   • Procedure: Decompression of tibial nerve at medial ankle.

   • Benefits: Alleviates neuropathic foot pain from nerve entrapment.

7. Lumbar Laminectomy with Nerve Root Decompression

   • Procedure: Removal of lamina segment to decompress dorsal roots.

   • Benefits: Improves radicular symptoms in cases of secondary spinal stenosis.

8. Peripheral Nerve Decompression

   • Procedure: Identify and release fibrous bands compressing nerves (e.g., ulnar nerve at the elbow).

   • Benefits: Reduces focal neuropathic pain and sensory deficits.

9. Achilles Tendon Lengthening

   • Procedure: Z-plasty of the tendon.

   • Benefits: Improves dorsiflexion range, aiding gait in patients with equinus contracture.

10. Orthotic Implantation (Dynamic Ankle–Foot Orthosis)

    • Procedure: Surgical insertion of guiding implants to support foot drop correction.

    • Benefits: Provides long-term mechanical support for ambulation.

---

Prevention Strategies

1. Early Diagnosis & Treatment: Initiate therapy at first symptoms to prevent irreversible axonal damage.

2. Regular Neurological Monitoring: Biannual EMG/NCS to detect subclinical progression.

3. Bone Health Management: Bisphosphonate prophylaxis for long-term steroid users.

4. Vaccinations: Pneumococcal and meningococcal vaccines before immunosuppression.

5. Infection Control: Prompt treatment of infections to avoid immune flares.

6. Smoking Cessation: Smoking impairs nerve repair; quitting supports regeneration.

7. Glycemic Control: In diabetics, tight glucose control reduces additive neuropathic risk.

8. Toxin Avoidance: Limit alcohol and neurotoxic chemotherapy agents.

9. Ergonomic Adaptations: Use padded gloves and supportive footwear to protect vulnerable areas.

10. Stress Management: Chronic stress can exacerbate immune dysregulation; employ relaxation techniques.

---

When to See a Doctor

Seek prompt medical attention if you experience:

• Rapidly progressing numbness or tingling over days to weeks

• New-onset balance problems or frequent falls

• Severe burning pain unrelieved by over-the-counter analgesics

• Signs of motor involvement (weakness, foot drop)

• Bowel, bladder, or autonomic symptoms (e.g., dizziness on standing)

Early evaluation—ideally within 2–4 weeks of symptom onset—allows more effective reversal of demyelination.

---

“Do’s” and “Avoid’s”

Do’s:

1. Follow your personalized home exercise program daily.

2. Use assistive devices (canes, braces) as prescribed.

3. Practice energy conservation techniques.

4. Eat a balanced diet rich in antioxidants.

5. Keep routine follow-up appointments with your neurologist.

6. Monitor blood pressure and blood sugar if on steroids.

7. Report new infections or fevers immediately.

8. Stay hydrated to support overall nerve health.

9. Use heat or cold packs for symptomatic relief as recommended.

10. Engage in gentle mind-body practices daily.

Avoid’s:

1. High-impact sports or heavy lifting that stress compromised nerves.

2. Skipping doses of immunotherapy or steroids.

3. Smoking and excessive alcohol consumption.

4. Overuse of non-steroidal anti-inflammatories without medical advice.

5. Ignoring early signs of relapse (increased numbness or pain).

6. Prolonged immobility without periodic movement breaks.

7. Self-adjusting immunosuppressant doses.

8. Exposure to extreme cold, which can worsen neuropathic pain.

9. Delaying vaccinations when immunosuppressed.

10. Bypassing foot and hand protective gear during activities.

---

Frequently Asked Questions (FAQs)

1. What causes sensory-predominant CIDP?
   Sensory-predominant CIDP arises when the immune system targets myelin on sensory fibers, often triggered by infections or unknown autoimmune factors.

2. How is CIDP diagnosed?
   Diagnosis relies on clinical examination, nerve conduction studies showing slowed conduction velocity, and sometimes nerve biopsy confirming demyelination.

3. Can CIDP be cured?
   There is no cure, but early, aggressive treatment often induces remission and prevents permanent nerve damage.

4. How long is treatment needed?
   Many patients require immunotherapy for 1–2 years; some may need long-term maintenance to prevent relapses.

5. Are there lifestyle changes that help?
   Regular, gentle exercise, balanced nutrition, stress management, and avoiding neurotoxins all support nerve health.

6. Is physical therapy essential?
   Yes. Targeted physiotherapy preserves strength, balance, and function, and reduces risk of falls.

7. What are the side effects of IVIg?
   Commonly headache, chills, or mild fever; rare but serious risks include thrombosis or renal impairment.

8. How do I manage fatigue?
   Use energy conservation techniques, plan activities with rest breaks, and avoid overexertion.

9. Can CIDP recur?
   Relapses occur in up to 50% of patients; close monitoring and maintenance therapy reduce this risk.

10. Is pregnancy safe with CIDP?
    Many women have successful pregnancies, but close coordination with neurology and obstetrics is needed for medication adjustments.

11. Can diet improve symptoms?
    While no specific diet cures CIDP, antioxidants and anti-inflammatory foods may support nerve repair and reduce pain.

12. When is nerve surgery considered?
    Surgery is reserved for decompression of entrapment neuropathies or tendon transfers for severe weakness, not as primary CIDP treatment.

13. Are there new therapies on the horizon?
    Experimental treatments—such as stem cell transplantation and monoclonal antibodies targeting specific immune pathways—show promise in early trials.

14. How do I cope with chronic pain?
    Combine pharmacological agents (e.g., neuropathic pain medications) with mind-body therapies like mindfulness and guided imagery.

15. Where can I find support?
    Patient advocacy groups, online forums, and multidisciplinary clinics offer education, emotional support, and resources for living with CIDP.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: July 07, 2025.